CIDP Disease Life Expectancy: What You Should Know

In general, CIDP disease life expectancy for patients is comparable to that of healthy counterparts, however, the quality of life may be significantly impacted. Quadriplegia (paralysis of the arms and legs), respiratory failure, and death rarely occur.  

 

Speak to a Specialist About Copay Assistance

(877) 778-0318

 

Highlights

• CIDP is a rare neurological disorder affecting nerves outside your brain and spinal cord. 
• CIDP disease life expectancy for patients is comparable to that of their healthy counterparts.
• Complications, coexisting medical conditions, and treatments impact life span rather than CIDP itself. 
• Long-term outlook is generally favorable, with only a fraction of people dying due to the disease or its complications. 
• Death rates have steadily decreased in the last few decades. 

 

A Quick Overview of CIDP

CIDP is a rare neurological disorder. It occurs when a person’s immune system attacks myelin (the fatty layer that protects the nerve fibers) in the peripheral nerves. Peripheral nerves lie outside your brain and spinal cord. 

About 30,000 people in the US live with CIDP [1].

 

How Does CIDP Affect Life Expectancy?

CIDP is unlikely to directly affect life expectancy, as evidenced in several studies. However, complications and coexisting medical issues can shorten life expectancy and cause a significant decrease in quality of life. 

For instance, the risk of anxiety, depression, and memory problems is higher in people with CIDP. Weakness and fatigue can negatively impact one’s ability to perform daily activities, possibly leading to depression [2].

Additionally, there may be a higher risk of suicide among people with neurological disorders [3].

Weakness of the legs can increase the risk of falls and injuries. Moreover, people with CIDP tend to have unnoticed or repeated injuries, which can impact their life span. 

Complications may also arise due to treatment for this condition. 

Death due to CIDP is rare. Thanks to effective treatments such as IVIG and plasma exchange (plasmapheresis), deaths due to CIDP have steadily decreased from 2002 to 2014 [4]. 

 

Can You Recover From CIDP?

Full recovery is possible. However, permanent loss of nerve function is frequent. Moreover, the chances of functional recovery decrease with age [5].

 

Does CIDP Get Worse Over Time?

Early treatment is crucial to keep the symptoms under control. Without treatment, the symptoms will likely worsen. Symptoms can include:

• Tingling or numbness in fingers and toes
• Fatigue 
• Weakness of the arms and legs
• Loss of balance

Left untreated, 1 in 3 individuals with CIDP will need a wheelchair. 

 

Get IVIG Copay Assistance | Your IVIG Treatment Info | Get IVIG Prior Authorization

Consult an IVIG Specialist

 

What Is the Long-term Outcome for People With CIDP?

According to a 2023 review, nearly 50% of individuals with CIDP had a favorable outcome and no disability [6].

Only a small fraction of people died due to the disease or treatment complications, and over 40% achieved remission. Remission is a period during which the signs and symptoms are reduced or no longer present.

Another study suggests that 13 – 24% of people have severe disabilities despite treatment, and about 40% of them need continuous immunosuppressant therapy [7].

In a 5-year follow-up study in Japanese CIDP patients [8]:

• 87% of the 38 participants were able to walk 5 years later.
• 26% experienced complete remission for over two years without treatment. 
• 39% still required immune treatments.
• 13% had severe disabilities.

 

CIDP Disease Life Expectancy: Frequently Asked Questions

What is the latest treatment for CIDP?

In February 2021, the FDA approved Pfizer’s Panzyga (IVIG) for the treatment of adults with CIDP. It is the first and only FDA-approved intravenous immunoglobulin with two maintenance dosing options to treat CIDP. 

Can nerves recover from CIDP?

Though permanent loss of nerve function is common, some people may have their nerve function restored. 

What Is the Success Rate of CIDP Treatment?

89 – 90% of people with CIDP respond to one of the first-line therapies: IVIG, plasma exchange, and corticosteroids [9].

 

REFERENCES:

1. School, McGovern Medical. “CIDP | Chronic Inflammatory Demyelinating | UTHealth Houston.” Neurology, Neurosurgery, Spine Care | UTHealth Neurosciences, 17 Oct. 2023, med.uth.edu/neurosciences/conditions-and-treatments/nerve-disorders/chronic-inflammatory-demyelinating-polyneuropathy.
2. Klehmet, J., Tackenberg, B., Haas, J. et al. Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy. BMC Neurol 23, 207 (2023). https://doi.org/10.1186/s12883-023-03223-5
3. Alejos, M et al. “Do patients diagnosed with a neurological disease present increased risk of suicide?.” “¿Existe mayor riesgo de suicidio en pacientes diagnosticados de una enfermedad neurológica?.” Neurologia, S0213-4853(20)30129-8. 22 Jun. 2020, doi:10.1016/j.nrl.2020.03.003
4. Zhang. (n.d.). Long Term Differential Outcomes of CIDP Patients After Using IVIG, Plasmapheresis, Or Corticosteroids: A Statewide Planning and Research Cooperative System (SPARCS) Study 2002-2014.
5. Hagen, K.M., Ousman, S.S. The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroinflammation 18, 78 (2021). https://doi.org/10.1186/s12974-021-02113-2
6. Al-Zuhairy, A., & Jakobsen, J. (2023). Outcome in chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis. Muscle & Nerve, 68(4), 388-396. https://doi.org/10.1002/mus.27820
7. Baek, Seol-Hee. “Insight Into the Prognostic Factors of Chronic Inflammatory Demyelinating Polyneuropathy.” Annals of Clinical Neurophysiology, vol. 22, Apr. 2020, p. 8. https://doi.org/10.14253/acn.2020.22.1.8.
8. Kuwabara, S et al. “Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.” Journal of neurology, neurosurgery, and psychiatry vol. 77,1 (2006): 66-70. doi:10.1136/jnnp.2005.065441
9. Allen, Jeffrey A et al. “Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?.” Journal of the neurological sciences vol. 408 (2020): 116497. doi:10.1016/j.jns.2019.116497

This information is not a substitute for medical advice or treatment. Talk to your doctor or healthcare provider about your medical condition prior to starting any new treatment. AmeriPharma Specialty Care assumes no liability whatsoever for the information provided or for any diagnosis or treatment made as a result, nor is it responsible for the reliability of the content.

AmeriPharma Specialty Care does not operate all the websites/organizations listed here, nor is it responsible for the availability or reliability of their content. These listings do not imply or constitute an endorsement, sponsorship, or recommendation by AmeriPharma Specialty Care.

This webpage may contain references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with AmeriPharma Specialty Care.